Hematopoietic cell transplantation (HCT) remains the only curative option for the majority of patients with myeloid malignancies. 1 The main risk factors associated with HCT are either due to transplantrelated mortality and morbidity that include acute and chronic GvHD or relapse. [1] [2] [3] These risks increase with patient age and comorbidities. 4 The median age of diagnosis for patients with myeloid malignancies is above 65 years and HCT strategies that use reducedintensity conditioning regimens (RIC) now allow HCT in older patients with AML and myelodysplastic syndrome (MDS). [5] [6] [7] The main principle of these approaches is to decrease regimen-related toxicities by relying mainly on the GvL effect rather than high-dose chemotherapy that kills malignant cells. Although RIC regimens may be associated with lower transplant-related mortality and morbidity, a higher incidence of relapse-related mortality has been observed. [5] [6] [7] Thus, identifying older patients with AML or MDS that will have the utmost benefit from HCT remains clinically challenging.
Recently, a composite end point of GvHD-free, relapse-free survival (GRFS) at 1 year after HCT was proposed as a reliable end point that can account for transplant-and relapse-related mortalities and morbidities. 8, 9 Prior studies have shown that the probability of GRFS among adult and younger patients with myeloid malignancies is~23-31% in the first year post HCT, but the probability of this end point in older adults who are undergoing RIC HCT is unknown. 8, 9 In this study, we investigated the rate of GRFS at 1 year after RIC HCT in older patients with AML and MDS.
We conducted a retrospective single-institution analysis of 93 consecutive patients of age ⩾ 60 years with AML, MDS and chronic myelomonocytic leukemia (CMML), according to 2008 World Health Organization criteria, 10 who received RIC HCT at the Cleveland Clinic between 2000 and 2014. Data were obtained from our institution's Unified Transplant Database that prospectively captures data on patient's clinical characteristics and outcomes. All included patients received grafts from HLAidentical sibling donors, unrelated donor or umbilical cord blood. Patients were excluded if they had received prior allogeneic HCT. This study was approved by the Cleveland Clinic's Institutional Review Board. All patients signed informed consent for their data to be used for research at the time of transplantation.
Events corresponding to the GRFS outcome included grade 3-4 acute GvHD, chronic GvHD (any grade), relapse or death from any cause. 8 Patients who did not have GRFS events within the first year after transplant were censored at 1 year. For patients with multiple events, the earliest event was used for the timing of GRFS. All outcomes were calculated from the date of transplant, and included the primary end point of GRFS and secondary end points of acute GvHD, chronic GvHD, relapse, non-relapse mortality (NRM), overall survival (OS) and RFS. OS, RFS and GRFS were estimated using the Kaplan-Meier method. All other outcomes were estimated using the cumulative incidence method. Stepwise Cox proportional hazards analysis was carried out with a variable entry criterion of 0.10 and a variable retention criterion of 0.05 to evaluate predictive factors for GRFS.
The clinical characteristics for the cohort are summarized in Table 1 . The median age at transplantation was 64 years and a large proportion of patients had HCT-comorbidity index (HCT-CI) scores of ⩾ 3 (45%). Conditioning regimens primarily consisted of busulfan/fludarabine (46%) or fludarabine/TBI (40%). Ninety-five percent of patients received calcineurin inhibitor and mycophenolate mofetil as GvHD prophylaxis.
The median time to ANC recovery (first of 3 days with neutrophil count 4500/uL) was 13 days (range, 1-77 days) and the median time to platelet engraftment (first of 3 days with platelet count 420 000/uL) was 15 days (range, 8-170 days). Table 1 presents the outcomes for our patient cohort. Figure 1 shows the GRFS, RFS and OS.
A total of 38 (41%) died within 1 year of transplant (19 (20.5%) from NRM and 19 (20.5%) from relapse-related mortality). Causes of death included: relapse 19 (50%), infection 7 (18%), acute GvHD 4 (11%), multi-organ failure 3 (8%), chronic GvHD 1 (3%) and others 4 (11%).
A total of 68 patients (73%) had GRFS event within 1 year of transplantation (Table 1) . Among them, chronic GvHD was the first event in 25 (37%), relapse in 24 (35%), death from any cause in 12 (18%) and acute GvHD in 7 (10%) patients. The probability of GRFS at 1 year post transplantation was 25% (95% CI: 16-34%; Figure 1) . In multivariate analyses, only prior history of autologous HCT was associated with worse GRFS (hazard ratio 3.5, 95% CI: 1.3-9.7; P = 0.016; Supplementary Table 1) .
In our analysis of older patients with AML, MDS and CMML receiving RIC HCT, 25% were alive at 1 year post transplant without experiencing any GRFS events. This probability is similar to prior reports that have primarily focused on younger adult patients with hematologic malignancies. In a cohort of 628 patients from the Center for International Blood and Marrow Transplant Research, 1-year probability of GRFS was 23%. 9 In another single-institution study of 907 patients at the University of Minnesota transplanted between 2000-2012, 8 1-year GRFS was 31%. In multivariable analysis, age, disease risk and donor type were significant prognostic factors for GRFS. Conditioning regimen intensity did not have any impact on GRFS in adults ⩾ 21 years old (21% vs 26%, P = 0.26). 8 It should be noted that the median age of patients in this study was 43.8 years with 222 patients (24%) younger than 21 years. It also included patients with ALL (24%) and lymphoma (12%), and 55% received myeloablative regimens. 8 This could explain the differences in the results compared with our study.
Our study has the limitations of a retrospective cohort study and represents a relatively small cohort of patients who were treated at a single institution. Validation in a large cohort from multiple institutions is needed to further evaluate the impact of GRFS end point on older patients with myeloid malignancies.
In conclusion, in patients ⩾ 60 years with myeloid malignancies who receive RIC HCT, 1-year GRFS is~25%. Traditional prognostic factors (for example, age, HCT risk stratification models, donor/graft source and disease risk) were not predictive of GRFS in this population. Our findings can assist clinicians in counseling older patients with these diseases about the risks associated with allogeneic HCT.
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